Arrowhead Pharmaceuticals, Inc. (ARWR): EBITDA
-$682.47M
Year ended 2026-09-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-09-30 | -$682.47M | n/m | 2026-11-12, From 2025-10-01 |
| 2025-09-30 | $120.55M | n/m | 2026-11-12, From 2024-10-01 |
| 2024-09-30 | -$584.18M | n/m | 2026-11-12, From 2023-10-01 |
| 2023-09-30 | -$194.30M | n/m | 2025-11-25, From 2022-10-01 |
| 2022-09-30 | -$169.81M | n/m | 2024-11-26, From 2021-10-01 |
| 2021-09-30 | -$142.44M | n/m | 2023-11-29, From 2020-10-01 |
| 2020-09-30 | -$88.96M | n/m | 2022-11-28, From 2019-10-01 |
| 2019-09-30 | $63.89M | n/c | 2021-11-22, From 2018-10-01 |
| 2018-09-30 | -$52.94M | n/m | 2020-11-23, From 2017-10-01 |
| 2017-09-30 | -$34.01M | n/a | 2019-11-25, From 2016-10-01 |
| No annual figure between 2014-09-30 and 2017-09-30. | |||
| 2014-09-30 | -$51.93M | n/m | 2016-12-14, From 2013-10-01 |
| 2013-09-30 | -$22.84M | n/m | 2015-12-14, From 2012-10-01 |
| 2012-09-30 | -$19.34M | n/m | 2014-11-25, From 2011-10-01 |
| 2011-09-30 | -$9.56M | n/m | 2012-12-28, From 2010-10-01 |
| 2010-09-30 | -$5.56M | n/a | 2011-12-20, From 2009-10-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2026-09-30 | -$682.47M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | -$214.42M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $38.59M | +12.5% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | -$2.08M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$37.92M | n/m |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$517.98M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $2.11M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$25.85M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $59.97M | +386.0% |
Compare ARWR, ZLAB, NATR, TVTX side by side · Screen every company in Pharmaceutical Preparations ↗